Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.
Congruence aims to submit CTA/IND applications for the programmes in early 2027. Credit: Minerva Studio / Shutterstock.com.
Subscribe to our email newsletter
The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-deficient genetic obesity, glucocerebrosidase 1 (GBA1)-driven Parkinson’s disease, and Alpha-1 antitrypsin deficiency.
The financing was co-led by Dimension and OrbiMed, with additional participation from Amplitude Ventures, BDC Capital’s Thrive Venture Fund, Driehaus, FSTQ, Investissement Quebec, Lumira and Silver Arc.
It will primarily fund the Phase I/Ib study of CGX-926, Congruence Therapeutics’ lead programme for MC4R-deficient genetic obesity, enrolling both healthy subjects and patients.
Congruence Therapeutics also plans to complete investigational new drug (IND)-enabling activities for two development candidates focused on GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin deficiency.
The company aims to submit clinical trial application (CTA) / IND applications for these programmes in early 2027.
Congruence Therapeutics co-founder and CEO Dr Clarissa Desjardins said: “Our mission is to translate biology, chemistry and protein structural insights into medicines that address disease at its molecular origin.
“In addition to CGX-926, we are advancing multiple proprietary and collaborative programmes. We thank our new and existing investors for their continued support.”
Dimension’s founder and managing partner Zavain Dar said: “Leveraging cutting-edge molecular dynamics and machine learning, Congruence has built a best-in-class platform to unlock an exciting modality of medicines in small molecule correctors.”
Congruence continues research collaborations, including an expanded multi-target partnership with Ono Pharmaceuticals covering neurology, immunology, and oncology targets.
Another collaboration involves drug discovery for a metabolic target with a global pharmaceutical company.
The company’s Revenir computational platform analyses dynamic protein states to predict small molecule modulation, supporting its pipeline of genetically validated targets with unmet medical needs.
